Ozanimod Archives -

Bristol-Myers Squibb’s Zeposia (ozanimod) is already tipped for blockbuster sales in its first indication – multiple sclerosis –

Data sets up ulcerative colitis expansion for BMS’ MS drug Zeposia

https://pharmaphorum.com/news/data-sets-up-ulcerative-colitis-expansion-for-bms-ms-drug-zeposia/

Bristol-Myers Squibb’s multiple sclerosis therapy ozanimod has been approved by the FDA right on schedule, but the company

BMS gets FDA nod for ozanimod, but launch will be delayed

https://pharmaphorum.com/news/bms-gets-fda-nod-for-ozanimod-but-launch-will-be-delayed/

Regulators in the US and EU have formally started their review of Celgene’s oral drug ozanimod for multiple

Celgene gets MS blockbuster-in-waiting ozanimod back on track

https://pharmaphorum.com/news/celgene-gets-ms-blockbuster-in-waiting-ozanimod-back-on-track/

The launch of Celgene’s multiple sclerosis drug, ozanimod, will be delayed after the company failed to submit key

Ozanimod launch delayed by failures in FDA application

https://pharmaphorum.com/news/ozanimod-launch-delayed-by-failures-in-fda-application/

Ozanimod